HUTCHMED performed very well in 23H1, making high growth for the full year more certain. Whether fruquintinib gets FDA approval in 23H2 will be a key milestone for the company to stand on a new level.
Boomeranged on Mon, 30 Oct 2023 10:31
We have seen over 35% share price rally after this insight was published. Obviously, the market is optimistic about the upcoming fruquintinib's FDA potential approval in Q4, and has priced in this catalyst. We remain bullish on Hutchmed, because with the potential breakthrough in internationalization and the financial performance of turning losses into profits, qualitative changes are taking place
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.